It was a pleasure to meet with Prof. Andrea Rubbert-Roth (Kantonsspital St Gallen, St Gallen, Switzerland) to discuss the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
The abstract ‘Clinical responses to upadacitinib or abatacept in patients with rheumatoid arthritis by type of prior biologic disease-modifying antirheumatic drug: Data from the phase 3 SELECT-CHOICE study.‘ was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- What did the SELECT-CHOICE study show us in terms of the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs? (0:22)
- What were the objectives of the analysis you are presenting? (1:09)
- What were the findings of this analysis? (1:55)
- What were the limitations of the analysis? (3:42)
- How will these findings impact the future use of JAK inhibitors in routine clinical practice? (4:30)
Disclosures: Andrea Rubbert-Roth discloses receiving honoraria for lectures and consultations from Abbvie, UCB, Gilead, Lilly, Pfizer, MSD, Sanofi, Roche and BMS.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
